Doxorubicin
- Generic Name
- Doxorubicin
- Brand Names
- Adriamycin, Doxil, Myocet, Caelyx pegylated liposomal, Zolsketil pegylated liposomal, Myocet liposomal (previously Myocet), Celdoxome pegylated liposomal
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 23214-92-8
- Unique Ingredient Identifier
- 80168379AG
- Background
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its deta...
- Indication
Doxorubicin is indicated for the treatment of neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue and bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinom...
- Associated Conditions
- AIDS-related Kaposi's Sarcoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Advanced Endometrial Cancer, Advanced Ovarian Cancer, Breast Cancer, Hodgkin's Lymphoma, Metastatic Bone Sarcomas, Metastatic Breast Cancer, Metastatic Soft Tissue Sarcoma, Metastatic Thyroid Cancer, Metastatic Urothelial Cancer, Multiple Myeloma (MM), Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Sezary Syndrome, Waldenström's Macroglobulinemia (WM), Advanced Thymoma, Advanced uterine sarcoma, Metastatic Bronchogenic Carcinoma, Metastatic Gastric carcinoma, Metastatic Neuroblastoma, Metastatic Ovarian carcinoma, Metastatic Wilms' tumor
- Associated Therapies
- -
Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 84
- Registration Number
- NCT04910126
- Locations
- 🇨🇳
Union Hospital，Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 174
- Registration Number
- NCT04884035
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇦🇺Local Institution - 501, Adelaide, South Australia, Australia
🇵🇱Uniwersyteckie Centrum Kliniczne, Gdansk, Poland
Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Institut Bergonié
- Target Recruit Count
- 80
- Registration Number
- NCT04874311
- Locations
- 🇫🇷
Centre Georges François Leclerc, Dijon, France
🇫🇷Institut Paoli Calmette, Marseille, France
🇫🇷Institut Curie, Paris, France
PanDox: Targeted Doxorubicin in Pancreatic Tumours
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- University of Oxford
- Registration Number
- NCT04852367
- Locations
- 🇬🇧
Oxford University Hospitals NHS Trust, Oxford, United Kingdom
Zanubrutinib in Combination with R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Yazeed Sawalha
- Target Recruit Count
- 24
- Registration Number
- NCT04850495
- Locations
- 🇺🇸
MUSC, Charleston, South Carolina, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
- First Posted Date
- 2021-04-15
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT04847063
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
- Conditions
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2022-09-16
- Target Recruit Count
- 78
- Registration Number
- NCT04835870
- Locations
- 🇨🇳
The First People's Hospital of Changzhou, Changzhou, Jiangsu, China
🇨🇳Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
🇨🇳The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
- Conditions
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 899
- Registration Number
- NCT04824092
- Locations
- 🇨🇳
Morphsys Research Site, Taoyuan, Taiwan
🇬🇧MorphoSys Research Site, Wolverhampton, United Kingdom
🇷🇺Morphosys research site, UFA, Russian Federation
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- Conditions
- Angioimmunoblastic T-cell LymphomaEnteropathy-Associated T-Cell LymphomaFollicular T-Cell LymphomaMature T-Cell and NK-Cell Non-Hodgkin LymphomaMonomorphic Epitheliotropic Intestinal T-Cell LymphomaNodal Peripheral T-Cell Lymphoma With TFH PhenotypePeripheral T-Cell Lymphoma, Not Otherwise Specified
- Interventions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 170
- Registration Number
- NCT04803201
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Memorial Hospital East, Shiloh, Illinois, United States
🇺🇸University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
- Conditions
- Ann Arbor Stage III Diffuse Large B-Cell LymphomaAnn Arbor Stage IIX (Bulky) Diffuse Large B-Cell LymphomaAnn Arbor Stage IV Diffuse Large B-Cell LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsPrimary Cutaneous Diffuse Large B-Cell Lymphoma, Leg TypeT-Cell/Histiocyte-Rich Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma Activated B-Cell TypeDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
- Interventions
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 422
- Registration Number
- NCT04799275
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸Kaiser Permanente-Anaheim, Anaheim, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.